Now ideas for wellness

About Meiji

At a Glance

At a Glance

Get to know Meiji at a glance – from our core business to our most important numbers.

Food

Our Nutrition Initiatives

Our Nutrition Initiatives

Our goal is to improve the lives of people of all ages around the world through nutrition, from infants to older adults, and we are dedicated to achieving this goal.

Pharmaceuticals

R&D

Medical needs are always diversifying – here's how Meiji is responding.

Year in Review

Year ended March 2025

Key Figures

Net Sales
¥1,154.0billion
4.4%
Operating Income
¥84.7billion
0.5%
Operating Income Ratio
7.3%
0.3percentage points
ROE
6.8%
0.1percentage points
Capital Expenditures
¥56.6billion
R&D Expenses
¥38.8billion

Breakdown by Segment

  • Food
  • Pharmaceuticals

Net Sales

Operating Income

Business Performance Analysis

Food
Net Sales
¥925.5billion
2.8%
Operating Income
¥64.6billion
0.5%
Income Analysis(Billions of yen)
Pharmaceuticals
Net Sales
¥229.6billion
11.4%
Operating Income
¥24.7billion
8.9%
Income Analysis(Billions of yen)

Capital Expenditures

  • Food
  • Pharmaceuticals

Food

¥40.6billion

Pharmaceuticals

¥15.6billion

Cash Dividends per Share / Dividend Payout Ratio

  • Cash Dividends per Share
  • Dividend Payout Ratio

Future Prospects

This is our Medium-term Business Plan,
FYE 3/2024 through FYE 3/2026.

FYE3/2024
Results
FYE3/2025
Results
FYE3/2026
Targets
(Initial plan)
Net sales ¥1,105.4 biliion ¥1,154.0 biliion ¥1,195.0 biliion
Operating income ¥84.3 billion ¥84.7 billion ¥91.0 billion
Operating income ratio 7.6% 7.3% 7.6%
ROE 6.9% 6.8% 7.0%
as of May 9, 2025

The Accounting Standard for Revenue Recognition is applied from FYE 3/2022. As such, the above figures are calculted based on assumption of accounting treatment changes related to revenue recognition.